Paysign Inc. Soars on Surging Growth and Margins

PaySign Inc Class B ((PAYS)) has held its Q1 earnings call. Read on for the main highlights of the call.

Paysign Inc. Class B delivered an upbeat earnings call that underscored a breakout quarter in both growth and profitability. Executives stressed that broad-based strength in pharma and plasma, coupled with disciplined cost control and strong cash generation, more than offset pockets of weakness and timing issues in plasma centers, tax rate, and SaaS monetization.

Record Revenue Growth

Paysign reported total revenue of $28.0 million, up 50.8% year over year and above the high end of guidance of $27.0 million to $27.5 million. Management framed the quarter as an early proof point toward full-year revenue of $106.5 million to $110.5 million, implying a robust 30% to 35% growth rate.

Strong Profitability & Operating Leverage

Net income more than doubled to $5.4 million, or $0.09 per diluted share, reflecting powerful operating leverage as the business scaled. Operating margin jumped to 23.8% from 13.4%, while adjusted EBITDA climbed 113.4% to $10.6 million and margin expanded to 37.8% from 26.7%.

Patient Affordability (Pharma) Momentum

Pharma and patient affordability revenue surged 81.9% to $15.7 million as claim volumes rose about 49% versus the prior year period. The business deployed more than $540 million in financial assistance in the quarter versus roughly $320 million a year ago and exited with 135 active programs, rising to 141 at the time of the call.

Plasma Business Growth and Cash Generation

Plasma revenue increased 24.9% to $11.7 million, with average monthly revenue per center ticking up to $6,671 from $6,517. The company ended the quarter with 573 centers, up 89 year over year, and highlighted the plasma segment as a key cash generator supporting $20.5 million in unrestricted cash and zero bank debt.

Gross Margin Expansion

Gross profit margin expanded to 65% from 62.9%, driven mainly by the higher contribution from pharma and other higher-margin offerings. Management emphasized that mix shift toward these richer-margin programs is structurally improving profitability even as they continue to invest for growth.

Efficient Expense Growth

Cost of revenues rose 42.2% and total operating expenses increased 25.5% to $11.6 million, both well below the pace of revenue growth. This gap demonstrated clear operating leverage as the company scaled its platform and spread fixed costs across a larger revenue base.

Robust Pipeline & Business Development

Following a busy industry conference at Assembia, the team cited a strong pipeline with more than 50 meetings and real-time deal wins. They expect to exceed the 55 net pharma program additions logged in 2025, with growth coming roughly evenly from new clients and expansions with existing customers.

Conservative Balance Sheet & Customer Deposits

Restricted cash climbed to $159 million, largely representing customer program deposits and funds held on cards, underscoring the scale of flows Paysign manages. Management also highlighted a conservative balance sheet with ample cash available for acquisitions or capital returns and about $6 million of remaining acquisition payments to Gamma over three years.

Active Plasma Center Count Below Guidance

Despite solid revenue per center, the active plasma center count ended the quarter at 573 compared with guidance of 589. Looking ahead to the next period, management expects 555 to 560 centers as one customer shutters 19 underperforming locations and another sells centers to a rival provider.

SaaS/App Not Yet Revenue-Generating

Paysign’s new SaaS and app offering for plasma centers remains in the investment phase and is not yet contributing revenue. Management is engaged with regulators and declined to provide a specific monetization timeline, signaling that investors should view this as a longer-term upside lever.

Higher Effective Tax Rate

The effective tax rate rose to 27.2% from 20.5% a year earlier, reducing the net income benefit from strong operating performance. The increase was tied mainly to discrete items linked to the higher stock price, which lessened the tax advantage of stock-based compensation.

Customer Concentration & Low-Performing Centers

One plasma customer sold centers to a competing provider, removing roughly $650,000 of last year’s revenue that carried subscale economics of less than $3,500 per month per site. Additional underperforming centers were closed or sold, highlighting some concentration risk but also a disciplined focus on network quality.

Seasonal & Mix-Driven Margin Variability

Management reminded investors that margins will not move up in a straight line because of seasonality and revenue mix. Pharma typically peaks in the first quarter and plasma is soft early in the year, so they expect margins to moderate later in the year even as total revenue continues to grow.

Guidance and Outlook

Paysign reaffirmed 2026 guidance for revenue of $106.5 million to $110.5 million, gross margin of 60% to 62%, net income of $13 million to $16 million, and adjusted EBITDA of $30 million to $33 million. The outlook assumes continued pharma momentum with 147 to 150 active programs by quarter end, steady plasma growth despite fewer centers, and ongoing balance-sheet strength with significant cash and no bank debt.

Paysign’s earnings call painted the picture of a company scaling quickly and profitably in two attractive niches while managing through tactical challenges in plasma centers and tax costs. For investors, the key takeaway is that strong top-line expansion, widening margins, and a growing pharma pipeline are driving the story, with optionality from new products yet to be realized.